SCNX (Scienture Holdings) Long-Term Debt: $0.00 Mil (As of Mar. 2026)


SCNX Scienture Holdings Inc SCNX
47 GF Score
Price $0.35
GF Value $0.35
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Scienture Holdings Long-Term Debt?

Scienture Holdings SCNX 47 Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates SCNX with a GF Score™ of 47/100 and a GF Value™ of $0.35 (Fairly Valued). The stock has 6 warning signs investors should review.

Scienture Holdings's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Scienture Holdings's annual Long-Term Debt increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.61 Mil) but then declined from Dec. 2024 ($0.61 Mil) to Dec. 2025 ($0.00 Mil).

Scienture Holdings  (NAS:SCNX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Scienture Holdings Long-Term Debt Related Terms

Scienture Holdings Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Scienture Holdings's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scienture Holdings Long-Term Debt Chart

Scienture Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.33 0.00 0.61 0.00

Scienture Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.09 1.58 0.00 0.00 0.00
SCNX
47GF Score
Scienture Holdings Inc SCNX
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Scienture Holdings (SCNX) has a Long-Term Debt of $0.00 Mil as of Mar. 2026.
Is Scienture Holdings' Long-Term Debt too high?
Scienture Holdings' current Long-Term Debt is $0.00 Mil. Overall, Scienture Holdings has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scienture Holdings' Long-Term Debt compare to WGRX and HEWA?
Scienture Holdings' Long-Term Debt of $0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Healthcare Providers & Services company?
A good Long-Term Debt depends on the Healthcare Providers & Services industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Scienture Holdings's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scienture Holdings stock overvalued right now?
Based on GuruFocus' analysis, Scienture Holdings (SCNX) is currently considered Fairly Valued. The stock's GF Value™ is $0.35, compared to a current price of $0.35 — trading 1.3% below its estimated fair value. The current Long-Term Debt is $0.00 Mil. Scienture Holdings' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Scienture Holdings (SCNX), the current Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scienture Holdings (SCNX) Overvalued in 2026?

Based on GuruFocus' analysis, Scienture Holdings stock appears to be undervalued. The current stock price of $0.35 is trading 1.3% below its estimated GF Value™ of $0.35. GuruFocus considers Scienture Holdings to be Fairly Valued.

Key valuation signals for SCNX:

  • Long-Term Debt: $0.00 Mil
  • GF Value™: $0.35 vs. price of $0.35 (1.3% below fair value)
  • GF Score™: 47/100 with 6 warning signs

No single metric tells the full story. See the SCNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scienture Holdings Business Description

Other Exchanges 4E4:Germany
Address 20 Austin Boulevard, Commack, NY, USA, 11725
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
47GF Score

Get the complete analysis for SCNX

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35
Price
$0.35
GF Value